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Abstract
Background: Alzheimer’s disease (AD) and cerebrovascular disease (CVD) including chronic small vessel disease of
the brain (SVD) are the most frequent causes of dementia. AD is associated with metabolism of amyloid precursor
protein (APP) and low levels of amyloid-b peptide (Ab) X-42 in the cerebrospinal fluid (CSF). CVD and SVD are
established risk factors for AD, brain white matter lesions (WML) are established surrogate markers for SVD and are
also associated with reduced CSF AbX-42.
A cohort survey was performed to examine whether SVD or acute CVD affects APP metabolism and to explore a
potential association between WML and APP metabolism in two groups; cognitively impaired patients, subjective
and mild (SCI and MCI) and stroke patients. Through measurements of CSF APP metabolite levels in patients with a
wide range of WML volumes, this study aimed to determine how SVD influences APP metabolism.
Methods: Sixty-three patients were included: 37 with subjective cognitive impairment (SCI) or mild cognitive
impairment (MCI) without stroke, and 26 after acute stroke. Chronic and acute WML volume and infarct volume
were determined by magnetic resonance imaging (MRI) post-scan processing, and CSF levels of a- and b-cleaved
soluble APP (sAPP-a and sAPP-b, AbX-38, AbX-40 and AbX-42) were determined. The Mann-Whitney test was used
to compare the patient groups. Chronic and acute WML volumes, infarct volume, age, and sex were used as
predictors for CSF biomarker levels in linear regression analysis.
Results: CSF levels of sAPP-a and sAPP-b were strongly correlated (r = 0.95, p < 0.001) and lower levels of these
biomarkers were found in the stroke group than in the SCI/MCI group; median sAPP-a 499.5 vs. 698.0 ng/mL
(p < 0.001), sAPP-b 258.0 vs. 329.0 ng/mL (p < 0.005). CSF levels of sAPP-a, sAPP-b, AbX-38, AbX-40 and AbX-42
were inversely correlated with chronic WML volume (p ≤ 0.005; p ≤ 0.01; p ≤ 0.01; p ≤ 0.05; p ≤ 0.05 respectively),
but not with acute WML or infarct volumes.
Conclusions: Lower CSF levels of sAPP-a and sAPP-b in the stroke group than in the SCI/MCI group and an
inverse correlation with chronic WML indicate that ischemia lowers the levels of CSF sAPP metabolites and
suggests that APP axonal transport or metabolism may be affected in SVD of the brain.
Background
Alzheimer’s disease (AD) and cerebrovascular disease
(CVD) are the most frequent causes of dementia. Famil-
ial AD is associated with metabolism of the transmem-
brane amyloid precursor protein (APP) and mutations
in the APP gene [1,2], while less is known about the
etiology of sporadic AD [3]. However, findings in
histopathology [4] and molecular imaging [5] imply that
amyloid metabolism is also involved in sporadic cases.
After fast axonal transport of APP to synaptic terminals
[6], a- or b-secretase cleaves the protein into soluble
APP (sAPP-a or sAPP-b) and C-terminal fragments
(aCTFs and bCTFs) [7]. Subsequent cleavage of bCTFs
(by g-secretase) yields amyloid b (Ab) peptides X-38,
X-40 and X-42 [8]. AbX-42 is prone to deposition in
amyloid plaques [9], and an association between low* Correspondence: per.selnes@medisin.uio.no
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levels of AbX-42 in cerebrospinal fluid (CSF) and pre-
sence of amyloid plaques has been shown both in mole-
cular imaging [5] and post-mortem histopathological
studies [10]. Low CSF AbX-42 is also a predictor of AD
[11]. APP and sAPP-a are important factors for neurite
outgrowth [12] and neuronal plasticity and memory
[13,14].
We have found similar CSF levels of sAPP-a and
sAPP-b in sporadic AD and mild cognitive impairment
(MCI) [15] to control subjects [16]. Subjective cognitive
impairment (SCI) [17] is a pre-MCI stage characterized
by subjectively impaired cognition which is not demon-
strable with objective screening tests. SCI [18], MCI,
white matter lesions (WML) [19] and stroke [20,21] all
increase the risk of dementia and AD. WML are estab-
lished surrogate markers of chronic small vessel disease
of the brain (SVD) [22,23] and are frequently seen on
T2-weighted magnetic resonance imaging (MRI) scans of
individuals with and without dementia [24], and are pre-
sent in increased amount in AD [25]. They are associated
with reduced CSF levels of AbX-42 in various diseases
[26-28], and an inverse correlation between WML
volume and CSF level of sAPP-a and sAPP-b has been
demonstrated in non-demented elderly people [29].
Experimental stroke [30] and ischemia [31] lead to an
increased production of APP, upregulation of b-secretase
activity [32], and an accumulation of Ab peptides and
APP around ischemic WMLs [31]. Axonal transport is
impeded both by WML and APP metabolites [33,34].
Thus, APP over-expression may then impede axonal
transport, also of APP, and impair neuronal plasticity and
survival [35]. In ischemic conditions, CSF levels of APP
metabolites may be influenced by increased gene expres-
sion, impeded axonal transport and deposition in plaques
(which mainly contributes to reduced levels of CSF
AbX-42) [10]. In the case of impeded transport, low cor-
tical levels of APP [14] and sAPP-a [13] may also contri-
bute to cognitive decline.
In this study, a hypothetical association between volume
of WML and CSF concentration of sAPP metabolites
(sAPP-a and sAPP-b) in cognitively impaired patients was
tested by comparing CSF levels of these metabolites in
patients with SCI or MCI to those in post-stroke patients
and to MRI-based quantitative measures of brain ischemia
(WML) in both patient groups. Through measurement of
APP metabolite levels in patients with a wide range of
WML volumes, this study aimed to determine how SVD
influences APP metabolism.
Methods
Patients with SCI and MCI were recruited from a univer-
sity-hospital based memory clinic between September
2005 and December 2007. Inclusion criteria were age
40-79, established SCI or MCI for at least 6 months,
Global Deterioration Scale [36] score 2 or 3 (scores 4 and
higher are per definition dementia) as determined from a
clinical interview, Clinical Dementia Rating [37] ≤ 0.5
and results of screening tests performed at time of inclu-
sion (mini-mental state examination MMSE [38]; Step-
wise comparative status analysis parameters 13-20 [39];
fluency, interference and numeral-letter items from the I-
flex [40]; and Cognistat [41]). Exclusion criteria were
impaired activities of daily living, established psychiatric
disorder, cancer, drug abuse, solvent exposure or anoxic
brain damage. Thirty-seven patients fulfilled all criteria,
and successfully underwent MRI and lumbar puncture.
Stroke patients were recruited from a university-hospi-
tal based stroke unit during 2007. Inclusion criteria for
these patients were: cortical and lacunar supratentorial
infarctions, classified by MRI, between 40 and 79 years
of age, and cognitive complaints but MMSE score >23,
no severe problems of language and visual/auditory
neglect. Exclusion criteria were a history of medical or
psychiatric disorder including depression. Twenty-six
patients fulfilled all criteria, and successfully underwent
MRI and lumbar puncture. Table 1 presents sex, age
and MMSE scores for each patient group. All patients
gave their written consent, and the regional ethics com-
mittee approved the study.
MRI
MRI scans were from two sites (site 1: 10 patients, all SCI/
MCI; site 2: 53 patients). Site 1: Siemens Symphony 1.5 T
(Siemens, Erlangen, Germany) with a conventional quadra-
ture head coil. Two 3 D magnetization-prepared gradient
echo (MP-RAGE), T1-weighted sequences in succession
(TR/TE/TI/FA = 2730 ms/3.19 ms/1100 ms/15◦, matrix =
256 × 192), 128 sagittal slices, thickness = 1.33 mm, in-
plane resolution of 1.0 × 1.33 mm. Site 2: Siemens Espree
1.5 T using two 3 D MP-RAGE, T1-weighted sequences in
succession (TR/TE/TI/FA = 2400/3.65/1000/8◦, matrix =
240 × 192), 160 sagittal slices, thickness = 1.2 mm, in-
plane resolution of 1.0 mm × 1.2 mm.
For the SCI/MCI patients MRI was performed after
inclusion, whereas it was performed 3 months after the
stroke for stroke patients. Acute stroke localization was
determined during the acute stage hospitalization. At
Table 1 Patient characteristics
Variable Stroke SCI/MCI
Sex Men (total) 20 (26) 20 (37)
Age Median 66.0 60.4
Range 42-78 43-77
MMSE Median 29.0 28.0
Range 23-30 23-30
SCI: subjective cognitive impairment, MCI: mild cognitive impairment, MMSE:
mini-mental state examination
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this stage, diffusion-weighted MRI was also performed if
infarct localization was not evident from cerebral com-
puted tomography and clinical examination. WML,
including white matter hyperintensities associated with
current or previous infarction(s), were quantified with a
semi-automated method in the Nordic ICE clinical
image processing and analysis software application (Nor-
dicNeuroLab AS, Norway). In the T2-weighted fluid
attenuated inversion recovery (FLAIR) images, pixel
values in white matter higher than two standard devia-
tions (SD) above mean pixel value were defined as
WML (Fig 1). White matter hyperintensities associated
with current or previous infarctions were classified as
acute or chronic WML. The former was also considered
likely to represent acute post-stroke changes, possibly
stroke penumbra volume and subtracted from total
WML volume in post-stroke patients to determine the
volume of chronic WML used for further analysis.
Using the FLAIR-weighted images, hypointensities
classified as current or previous infarctions were quanti-
fied by manually assigning a freehand region of interest
to the area. The areas of each slice were added and mul-
tiplied with slice thickness to obtain total volumes.
Images from one MCI patient were excluded due to
motion artifacts.
CSF
CSF samples were collected by lumbar puncture through
the L3/L4 or L4/L5 intervertebral-space. The lumbar
puncture was performed consecutively after inclusion in
the SCI/MCI group or, in the stroke group (7-10 days
post stroke). CSF was collected in a polypropylene tube
and centrifuged at 2,000 × g at +4°C for 10 min. The
supernatant was removed, gently mixed to avoid possi-
ble gradient effects, and stored within one hour at
-80°C, pending biochemical analyses.
CSF concentrations of sAPP-a and sAPP-b, and
AbX-38, AbX-40 and AbX-42 were determined using the
MSD® sAPP-a/sAPP-b Multiplex Assay and MSD® Ab Tri-
plex Assay as described by the manufacturer (Meso Scale
Discovery, Gaithersburg, MD, USA). Coefficients of varia-
tion were < 10% for all analyses. All analyses from the
MCI and stroke groups were performed in the same batch.
Statistics
The statistics software package PASW 18 (SPSS Inc,
USA) was used for statistical analysis. Linear regression
was used to regress out age and sex, providing standar-
dized residuals for further use. Due to skewed data, the
Mann-Whitney test was used on these residuals to com-
pare for group differences.
Pearson correlation coefficients between the CSF vari-
ables and the WML volumes were determined. To
assess predictors for APP metabolites, scanner and sex
were linearly regressed out from chronic WML and
acute WML, again providing standardized residuals for
further use. Consecutively, age, acute WML volume and
chronic WML volume were entered as independent
variables for all APP metabolite values. The different
APP metabolites were sequentially entered as dependent
variables in linear regression analysis.
Results
After regressing out age and sex from the biomarkers, the
median CSF sAPP-a and sAPP-b levels were significantly
lower (p < 0.001 for sAPP-a and p < 0.005 for sAPP-b) in
the post-stroke patients than in the SCI/MCI patients.
There were no significant differences in CSF levels of Ab
X-38, X-40 and X-42 between the two groups. The
volume of chronic WML was higher in the stroke group
than in the SCI/MCI group, but this difference was not
significant (Table 2). The volume of acute post-stroke
changes (infarct volume and surrounding WML halo) did
not correlate with levels of CSF APP metabolites (data
not shown). sAPP-a and sAPP-b levels were linearly
related in both the stroke (r = 0.942, p < 0.001) and the
SCI/MCI (r = 0.955, p < 0.001) groups (Fig 2).
Most patients with high chronic WML volumes had
low CSF sAPP-a (Fig 3), and a clear negative correlation
between the two variables was seen (r = -0.36, p < 0.01).
A similar relation was seen between chronic WML
volumes and CSF sAPP-b (r = -0.33, p < 0.05). In the
regression analyses, chronic WML volume was a signifi-
cant predictor for all examined CSF APP metabolites;
Figure 1 Visualization of chronic white matter lesions obtained
by MRI. The hyper-intense areas in the FLAIR images (in red) are
overlain onto the T1 images and shown in three dimensions. The
ventricular walls (arrows), adjacent periventricular and subcortical
hyper-intensities are visualized.
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p ≤ 0.005 for sAPP-a, p ≤ 0.01 for sAPP-b and AbX-38
levels, and p ≤ 0.05 for AbX-40 and AbX-42 (Table 3).
When repeating this analysis separately for the post-
stroke and SCI/MCI groups, chronic WML still pre-
dicted sAPP-a and sAPP-b in the SCI/MCI group (p ≤
0.005 for both sAPP-a and sAPP-b), but not in the
post-stroke group. Age was not significantly related to
sAPP, but significantly predicted higher levels of AbX-
38 (p ≤ 0.01) and AbX-40 (p ≤ 0.05). Sex and scanner
site were not significantly related to any of the metabo-
lites (data not shown).
Discussion
We have shown that CSF levels of sAPP metabolites are
lower in post-stroke patients than in SCI/MCI patients.
There was an inverse relation between chronic, but not
acute WML volume and all examined CSF APP metabo-
lites across the groups. This suggests that the reduction
is associated with the severity of chronic, but not acute
ischemic disease.
One limitation of our study is that it did not include a
healthy control group. It may therefore be argued that
an alternative interpretation of our results would be that
there was an increase of APP metabolite levels in the
SCI/MCI group instead of a decrease in the post-stroke
group. At least two pieces of evidence argue against this
interpretation. Firstly, we did not see any significant dif-
ference in CSF levels of sAPP between controls and
MCI patients in an earlier study from our laboratory
[16]. Unfortunately however, the results from this study,
although employing the same sAPP assay, cannot be
directly compared to those in the present investigation
due to batch-to-batch variation in sAPP concentration
between different kits. Secondly, the inverse correlation
of CSF sAPP levels with WML volume seen in the pre-
sent study, as well as in an earlier investigation [29],
suggest that subcortical changes are associated with
sAPP reductions. Similar results have been reported in
Table 2 CSF concentrations of APP metabolites in two
patient groups
Variable Stroke
median, (SD)
SCI/MCI
median, (SD)
p
CSF sAPP-a ng/mL 499.5 (168.9) 698.0 (248.4) <0.001
CSF sAPP-b ng/mL 258.0 (74.2) 329.0 (101.4) <0.005
CSF Ab X-38 pg/L 1048.0 (576.9) 1141.0 (810.1) n.s.
CSF Ab X-40 pg/L 5989.0 (1777.6) 6323.0 (2209.3) n.s.
CSF AbX-42 pg/L 485.5 (167.5) 483.0 (227.7) n.s.
Chronic WML cubic mm 5051.8 (11569.0) 971.0 (6105.8) n.s.
Group differences after age and sex have been corrected for by linear
regression. CSF sAPP-a and sAPP-b are significantly lower in the stroke group
as compared to the SCI/MCI group. n.s.: not significant.
Figure 2 Graph showing the correlation between the CSF
levels of sAPP-a and sAPP-b in both groups of subjects.
Figure 3 Plot of CSF sAPP-a against chronic white matter
lesion (WML) volume. There were lower levels of APP metabolites
in some patients with increased volumes of chronic WML.
Table 3 Chronic and acute white matter lesion volumes
as predictors for APP metabolites in all patients.
Dependent Variables Independent variables p (beta)
cWML aWML Age
CSF sAPP-a ≤0.005 n.s. n.s.
(-0.396)
CSF sAPP-b ≤0.01 n.s. n.s.
(-0.369)
CSF AbX-38 ≤0.01 n.s. ≤0.01
(-0.359) (0.371)
CSF AbX-40 ≤0.05 n.s. ≤0.05
(-0.357) (0.309)
CSF AbX-42 ≤0.05 n.s. n.s.
(-0.273)
Chronic WML significantly predicts CSF levels of APP metabolites.
cWML = chronic WML, aWML = acute WML.
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other diseases that are characterized by white matter
changes, including multiple sclerosis [42] and dementia
in acquired immunodeficiency syndrome [43]. It should
be noted that Lewczuk and colleagues recently reported
higher CSF concentrations of sAPP in patients with cog-
nitive impairment (CI) and other neurochemical CSF
findings characteristic of AD, than in patients with CI
without CSF findings characteristic of AD [44]. Impor-
tantly, however, this study did not include a healthy
control group and it is not unlikely that a significant
number of the cognitively-impaired individuals without
AD-like CSF biomarker changes in fact suffered from
chronic cerebrovascular disease.
Our finding that increased chronic WML volume pre-
dicts lower sAPP metabolites is however clear-cut, and
is most easily interpreted in favor of reduced sAPP
metabolites in the stroke group. When repeating this
analysis separately in the post-stroke and SCI/MCI
groups, the prediction was not, however, significant in
the stroke group, but was still significant within the
SCI/MCI group. As CVD both increases APP produc-
tion and impedes transport, this suggests that the net
negative effects on APP levels occur at mild to moderate
WML levels. Also, the stroke group was somewhat
smaller than the SCI/MCI group, and this might explain
why the prediction was not significant within the stroke
group alone. In accord with earlier findings [16], sAPP-
a and sAPP-b levels were very tightly correlated, indi-
cating that the mechanism for the reduction lays
upstream of a- and b-secretase activity. Energy-depen-
dent fast axonal transport of APP [45] may well suffer
in chronic ischemic brain disease affecting white matter
tracts, resulting in reduced axonal transport of the pre-
cursor protein [34], reduced substrates for the secretases
resulting in the observed reduction in metabolite levels
in the CSF. Alternatively, ischemia may have an effect
on earlier stages, e.g. reduce APP gene expression, but
observations in experimental ischemia suggest that this
is less likely [30,31].
Chronic WML volume predicts levels of both sAPP
metabolites and Ab peptides, but there is a significant
difference between the post-stroke and the SCI/MCI
groups for sAPP, suggesting that for the amyloid b pep-
tides there is more extensive interplay with other fac-
tors. In a previous study [46], acute stroke was not
shown to have a significant short term effect on levels
of AbX-42. However, as human Ab clearance rates are
close to 10% per hour [47]; changes temporally related
to acute stroke onset are not expected to be detected in
the present study.
Conclusions
In the patient group as a whole, there was a strong corre-
lation between CSF sAPP-a and sAPP-b concentrations.
An inverse relationship was demonstrated between the
volume of chronic WML and CSF APP metabolites
(sAPP-a, sAPP-b, Ab X-38, X-40 and X-42) in both
stroke patients and SCI/MCI patients. In addition, there
were lower levels of CSF sAPP-a and sAPP-b in the
stroke group when compared to the SCI/MCI-group.
This suggests that ischemia influences APP metabolism
probably through inhibition of fast axonal transport of
APP. If confirmed, the present results implicate new
mechanisms for reduction of CSF APP metabolites,
including CSF AbX-42, which is a predictor for develop-
ment of AD.
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